MARKET OUTLOOK

Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic spontaneous urticaria (CSU) to standard doses of antihistamines, although claims data analysis reveals positive trends among the more-recent second-generation antihistamines Clarinex and Claritin. Vistaril and montelukast are also key drugs in the CIndU therapy market, and both are often used in combination therapy. Indeed, current treatment guidelines recommend the use of leukotriene receptor antagonists (i.e., montelukast) as add-on treatment. Biologics are used mainly as later-line therapy for CIndU, but because no biologics have been approved for the indication, they must be used off-label. Thus, more-effective drugs approved for CIndU are needed.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CIndU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CIndU patients?
  • How have TNF inhibitors, Xolair, and second-generation antihistamines been integrated into the treatment algorithm, and what are their source of business?
  • What percentage of CIndU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of CIndU patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Inducible Urticaria (US)
    • Treatment Algorithms CDA Chronic Inducible Urticaria US May 2020

Author(s): Yingdee Unhavaithaya

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.


Related Reports

Urticaria | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Spontaneous Urticaria (US)

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious known stimulus. Dr...

View Details

Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Spontaneous | US | 2019

Market Outlook Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer...

View Details